Drug
Naporafenib clinical trials
Also written LXH254 and ERAS-254.
How studies write it
Studies that test it under each name
Name
Studies by the year they started
4 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Novartis Pharmaceuticals (2) · Erasca, Inc. (2)
Often tested with
Tested in the same studies.
Trametinib (3) · Ribociclib (1) · Rineterkib (1) · Batoprotafib (1) · Spartalizumab (1) · Tislelizumab (1)
Studies
Open first, then newest update. How each study uses naporafenib is read from its arms, and is right about nine times in ten.
Testing it · 4
- Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaActive, not recruitingPhase 2Novartis PharmaceuticalsNCT04417621Written as LXH254
- A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X MutationsActive, not recruitingPhase 1Erasca, Inc.NCT05907304Written as Naporafenib
- A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)Active, not recruitingPhase 3Erasca, Inc.NCT06346067Written as Naporafenib
- A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal CancerTerminatedPhase 1Novartis PharmaceuticalsNCT04294160Written as LXH254
Given in every arm · 3 — naporafenib is usual care beside what is tested
- Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCActive, not recruitingPhase 1Novartis PharmaceuticalsNCT03333343Written as LXH254
- A Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaTerminatedPhase 1Novartis PharmaceuticalsNCT02974725Written as LXH254
- Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway AlterationsTerminatedPhase 1Novartis PharmaceuticalsNCT02607813Written as LXH254
Codes
What other systems call naporafenib · ClinicalTrials.gg INT001956
- MeSH (NLM) C000723373naporafenibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 15JL80DG6HNAPORAFENIBConfirmed FDA, NLM
- NCI Thesaurus C125003NaporafenibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723373 | naporafenib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 15JL80DG6H | NAPORAFENIB | Confirmed FDA, NLM |
| NCI Thesaurus | C125003 | Naporafenib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.